KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2025)

Alnylam Pharmaceuticals' Inventory history spans 8 years, with the latest figure at $82.7 million for Q4 2025.

  • For Q4 2025, Inventory rose 5.36% year-over-year to $82.7 million; the TTM value through Dec 2025 reached $82.7 million, up 5.36%, while the annual FY2025 figure was $82.7 million, 5.36% up from the prior year.
  • Inventory reached $82.7 million in Q4 2025 per ALNY's latest filing, up from $75.4 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $131.9 million in Q1 2023 to a low of $65.6 million in Q1 2025.
  • Average Inventory over 5 years is $90.0 million, with a median of $85.4 million recorded in 2021.
  • The largest YoY upside for Inventory was 67.96% in 2023 against a maximum downside of 30.87% in 2023.
  • A 5-year view of Inventory shows it stood at $86.4 million in 2021, then skyrocketed by 49.33% to $129.0 million in 2022, then tumbled by 30.87% to $89.1 million in 2023, then dropped by 11.93% to $78.5 million in 2024, then grew by 5.36% to $82.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Inventory are $82.7 million (Q4 2025), $75.4 million (Q3 2025), and $71.7 million (Q2 2025).